Clinical trial · Observational
18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma
A Prospective Exploratory Study Evaluating the Diagnostic Usefulness of 18F-mFBG PET Imaging in Pheochromocytoma
NCT06813742CI-TRIAL-00093288recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with pheochromocytoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pheochromocytoma | Adrenal Gland Pheochromocytoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-MFBG | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 18F-MFBG PET/CT in Pheochromocytoma
- description
- Each patient receive a single intravenous injection of 18F-MFBG 5.55 MBq/kg and undergo PET/CT or PET/MR scan after 60 min post-injection.
- interventionNames
- Drug: 18F-MFBG
Primary outcomes (1)
- measure
- Correlation between positive and negative 18F-mFBG PET/CT or PET/MR Imaging and pathological diagnosis and treatment effect in patients with pheochromocytoma.
- timeFrame
- through study completion, an average of 1 year
- description
- Main outcome measure
Secondary outcomes (1)
- measure
- False positive and false negative results of 18F-mFBG PET/CT or PET/MR Imaging in patients with pheochromocytoma.
- timeFrame
- through study completion, an average of 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged 30-80 years old, primary school or above, with a regular caregiver; 2. Clinically diagnosed patients with pheochromocytoma; 3. Can provide informed consent, can understand and comply with the study requirements. Exclusion Criteria: 1. Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system; 2. Uncontrolled hypertension or high-risk BP (i.e., systolic BP \> 180 mmHg or diastolic BP \> 110 mmHg); 3. Patients with mental disorders or primary affective disorders; 4. Unable to understand and adhere to the study protocol or provide informed consent; 5. Contraindications to PET imaging (including pregnant women, lactating women, and women of childbearing age with recent childbearing plans, etc.); 6. Allergy to imaging agents; 7. Patients who were unable to cooperate with PET scanning, such as hypoglycemia, severe pain or tremor.
References
Publications (0)
Data not yet available
No reference posted for this study.